It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Persistent pathogens have evolved to avoid elimination by the mammalian immune system including mechanisms to evade complement. Infections with African trypanosomes can persist for years and cause human and animal disease throughout sub-Saharan Africa. It is not known how trypanosomes limit the action of the alternative complement pathway. Here we identify an African trypanosome receptor for mammalian factor H, a negative regulator of the alternative pathway. Structural studies show how the receptor binds ligand, leaving inhibitory domains of factor H free to inactivate complement C3b deposited on the trypanosome surface. Receptor expression is highest in developmental stages transmitted to the tsetse fly vector and those exposed to blood meals in the tsetse gut. Receptor gene deletion reduced tsetse infection, identifying this receptor as a virulence factor for transmission. This demonstrates how a pathogen evolved a molecular mechanism to increase transmission to an insect vector by exploitation of a mammalian complement regulator.
African trypanosome infections can persist for years, but immune evasion mechanisms are not fully understood. Here, Macleod et al. identify a trypanosome receptor for mammalian factor H, a negative regulator of the alternative complement pathway, that increases parasite transmission to tsetse flies.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 University of Cambridge, Department of Biochemistry, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934)
2 University of Montpellier, Intertryp, IRD, Cirad, Montpellier, France (GRID:grid.121334.6) (ISNI:0000 0001 2097 0141)
3 University of Bristol, School of Biological Sciences, Bristol, UK (GRID:grid.5337.2) (ISNI:0000 0004 1936 7603)
4 University of Edinburgh, Institute for Immunology and Infection Research, School of Biological Sciences, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
5 University of Oxford, Department of Biochemistry, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
6 Oxford Brookes University, Department of Biological and Medical Sciences, Oxford, UK (GRID:grid.7628.b) (ISNI:0000 0001 0726 8331)
7 University of Cambridge, Department of Biochemistry, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); AstraZeneca R&D, Department of Antibody Discovery and Protein Engineering, Cambridge, UK (GRID:grid.417815.e) (ISNI:0000 0004 5929 4381)
8 AstraZeneca R&D, Department of Antibody Discovery and Protein Engineering, Cambridge, UK (GRID:grid.417815.e) (ISNI:0000 0004 5929 4381)
9 London School of Hygiene and Tropical Medicine, Faculty of Infectious and Tropical diseases, London, UK (GRID:grid.8991.9) (ISNI:0000 0004 0425 469X)